Clinical Trials

 
 
 
If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815-730-3098.
 
 
 
 

Colorectal

 
ISO-CC-007: 1st-line Metastatic Colorectal
A randomized, multi-center, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab in patients with advanced colorectal cancer
 
 
 

Lymphoma

 
Relapsed/Refractory Hodgkin Lymphoma – E4412
A Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

 
 
 

Melanoma

 
EA6134 : First-Line Metastatic Melanoma
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
 
 
 

Myeloma

 
EAA173: 1st-line high risk Smoldering Multiple Myeloma
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma
 
 
 

Prostate

 
EA8153 : 2nd line Metastatic Prostate
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
 
 
 

Blood

 
Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study
 
 
 
 
 

Lung

 
NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)
 
M14-239 : 2nd-Line NSCLC
Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
 
EA5163 : Advanced Nonsquamous NSCLC
A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
 
ANAM 17-20 : Weightloss in NSCLC
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
 
AB154CSP0002: First-Line Metastatic Squamous or NonSquamous NSCLC w/ PD-L1 >50%
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122 and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
 
 
 

Renal

 
A031704 - 1st-line Metastatic Renal Cell
PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab in metastatic untreated Renal Cell Cancer
 
 
 

Various

 
Collection and Distribution of Biofluids and Tumor Tissue Biospecimens for Research Purposes - IPROCESS-BSG-001-US Advarra IRB 1/14/2019 - Bluestar Genomics
Untreated - Bladder, Brain, Breast, Cervical, Colorectal, Esophageal, Gastric, Kidney, Liver, Lung, Ovarian, Pancreatic, Prostate, Uterine and AML
 
Exact Sciences 2018-01 : Biomarkers on Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors: Breast, Lung, Coorectal, Prostate, Bladder, Uterine, Kidney/Renal Pelvis, Pancreatic, Liver, Stomach, Ovarian or Esophageal
 
VS-0145-401: Registry for CLL, SLL and FL
PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3Kinhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
 
S1815 CIRB: First-Line Biliary Tract Cancers
A Phase III Randomized Trial Of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers
 
 
 
 
 

Breast

 
A011502 : Adjuvant Breast
A randomized phase III double blinded placebo-controlled trial of aspirin as adjuvant therapy for HER2 negative breast cancer: the ABC trial
 
NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
 
NRG- BR004 : First-line HER2+ Metastatic Breast
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
 
S1418 : Adjuvant Breast Triple Negative
A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
 
EA1181: First-Line Stage II and IIIa HER2+ prior to TX Breast Cancer
§ (Compass HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
 
M19-992: Second-line Locally Advanced or Metastatic HR+ Breast Cancer
A Phase 1b Study of Venetoclax and Capecitabine In Subjects with Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Experienced Disease Progression During or After CDK4/6 Inhibitor Therapy
 
 
 

Urothelial

 
1st-line Locally Advanced/Metastatic Urothelial Cancer – MK7902-011
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)
 
 
 
 
 

Our Team

 
 
 

Medical Director of Clinical Research

 
Dr. Nafisa Burhani, MD
 
 
 
 
 

Manager of Clinical Research

 
Karen Sceniak, CCRC
ksceniak@jolietoncology.com
 
 
 
 
 

Clinical Research Coordinators

 
 
 
 
 

Data Manager

 
 
 
 
 

Regulatory Affairs Manager